Webster, TX – According to filings with the U.S. Securities and Exchange Commission, Cao Pharmaceuticals is raising $16,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Zhisong Cao played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cao Pharmaceuticals

Cao Pharmaceuticals is an early clinical stage oncology drug development company with a rich and deep history. We are committed to develop highly effective drugs from a natural plant extract with very low or readily manageable toxicity for the treatment of all solid tumors (i.e. colon, lung, breast, prostrate, melanoma, sarcoma, pancreatic, liver, etc.) and lymphoma. And with much shorter development timeframes compared to traditional chemotherapies.Cao Pharmaceuticals is currently conducting a Phase I trial with their lead drug. And Phase II trials are scheduled to start Q1 2018.

To learn more about Cao Pharmaceuticals, visit http://www.caopharmaceuticals.com/

Contact:
Zhisong Cao, Chief Executive Officer
832-283-7705
zhisongc@caopharmaceuticals.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved